Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Besides azoles, candins and the polyene class of antifungals there is not much to select from when it comes to systemic fungal infections. Until the recent arrival of voriconazole and posaconazole, infections caused by molds always required amphotericin B to control. Only for Candida several good treatments exist on the Continue reading Nikkomycins Are Finally Getting Some Respect
Despite all the concern about the emergence of CRE pathogens worldwide, it is quite difficult to obtain hard quantitative, prospectively collected incidence figures. A recent article by Robert [1] and colleagues provides useful data from France. Using a practical definition of carbapenem-non-susceptibility (ertapenem > 0.5, imipenem, meropenem > 2, doripenem > 1), Continue reading CRE Surveillance Data from France
Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name. ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago. This is the ‘Carbavance’ which Continue reading What’s in a Name? Would ‘Carbavance’ Still Smell as Sweet?